TORONTO (PRWEB) November 02, 2020
All clinical trials face challenges, but for rare disease trials, there are additional and unique challenges. Recruiting patients with the accurate rare disease diagnosis is a significant hurdle, followed by the challenges of addressing the difficulty and strain of these diseases on the patients themselves throughout the course of the study. With many rare diseases being genetic in nature, outcomes and decisions weigh heavily on the patient families.
For rare oncology trials, it becomes even more complex, from recruiting patients with specific biomarkers and genetic characteristics to navigating complex logistics and timing with individualized therapies and addressing evolving trial designs. A high number of study sites are required to enroll a very small number of patients. Statistical significance may be limited as well, so analysis may hinge on individual patients and historical comparison. Additionally, working with regulatory authorities throughout the process is critical.
Join Deb Kientop, Vice President, Strategic Development, Oncology; Dr. Marie Bonneterre, Vice President, Medical Affairs, Oncology; and Rachael Young, Director, Feasibility, all from Synteract, in the live webinar on Tuesday, November 17, 2020 at 11am EST (4pm GMT/UK) in which they will address these challenges.
For more information or to register for this event, visit Rare Cancers: Special Considerations for Complex Clinical Studies.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.